Redeye is mostly positive to today’s news that Saniona has renegotiated its loan from Formue Nord.
As a part of its cost-saving program, DT today initiated change negotiations which may end up in a t...
Tumorad i skarpt läge Efter år av utvecklingsarbete har det blivit dags att inleda utvärdering av Tu...
Carlsquare Equity Research sammanfattar sina första intryck av Spotlight Groups kv2-rapport.
We lower '23e-'25e sales by 5-8%Algo rebound as early as H2'23'23e-'24e EV/EBITDA of 27x-5x What to ...
Redeye comments on the inclusion of the last patient in the Lenvima arm of the phase IIa trial of fo...
Marimekko publishes its Q2 result on Thursday, Aug 17th.
Redeye initiates coverage of Ortoma, a Swedish medtech company in early stage commercialisation with...
Redeye retains its positive view of Efecte following the Q2 report.
Redeye provides a brief update on BeammWaves, after its Q2’23 report.
Redeye comments on today’s news that Annexin has seen initial signals of effect in the ongoing phase...
Negativ organisk tillväxt och marginalpress… Med accelererande avveckling av kopparnäten såg Sverige...
Redeye states its view on Hoylu’s Q2 2023 report, announced earlier today.
Redeye comments on Remedys Q2-report. Revenue was somewhat below our estimates while EBIT was clearl...
Redeye comments on Coala Life’s Q2’23 report, noting stable sales progress driven mainly by increase...
Aspo’s outlook worsened this spring, and Q2 results fell below reduced estimates.
Carlsquare Equity Research sammanfattar sina första intryck av H&D Wireless kv2 2023-rapport.
Etteplan reported Q2 results that were below our estimates.
Redeye retains its positive view of Efecte following a Q2 report in line with our expectations.
Redeye updates on G5 following its Q2-results where topline was soft while results were close to our...
